News and Announcements
Antisense Therapeutics to Present at MS Conference
- Published August 31, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Antisense Therapeutics Ltd (ASX:ANP) has recently reported on data showing ATL1102 significantly reduces the number of active multiple sclerosis (MS) brain lesions that convert to ‘Black Holes’ is to be presented at the 7th Joint ECTRIMSACTRIMS Meeting in Paris, France 25-28 October 2017.
KEY TAKEAWAYS:
- The world’s largest international conference devoted to basic and clinical research in MS.
Professor Barkhof, said “the ATL1102 ‘Black Holes’ data is most compelling which is reflected in its selection for late-breaker poster presentation”.
Importantly, the positive effect of ATL1102 suggests that along with its action in reducing the number of new inflammatory brain lesions, ATL1102 may also be neuroprotective by reducing damage to axons in the lesions and thereby slow the MS disease progression.
Further information on the meeting can be found at https://www.ectrims-congress.eu/2017.html
Company Updates
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Asset over thematic: Centuria’s Andrew Essey warns against ‘blanket strategies’ as global capital eyes Australia
Relying solely on broad macroeconomic trends is the single biggest mistake property investors make today. Centuria Capital CIO Andrew Essey explains why asset-level “lettability” always trumps the overarching sector thematic, and reveals where global institutional capital is quietly pivoting to capture high-octane returns.
Material gains: Swinburne spin-out EntroMat takes aim at $160b global market
Traditional metallurgy has hit a performance wall. Discover how Swinburne University spin-out EntroMat is leveraging physics-based AI and circular critical minerals to engineer high-entropy alloys capable of surviving the world’s most extreme industrial environments.
Backed By Leading Investment Groups and Family Offices
